Zhi-ming Zeng - Publications

Anlotinib Combined With Toripalimab as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Prospective, Multicenter, Phase II Study.

Journal: The oncologist

Published: March 01, 2023

Case Report: A case of hepatocellular carcinoma with aberrant right hepatic artery treated with transarterial chemoembolization and infusion chemotherapy separately to bilobar lesion combining with systemic therapies and sequential hepatectomy.

Journal: Frontiers in oncology

Published: February 14, 2023

Radiographic and α-fetoprotein response predict pathologic complete response to immunotherapy plus a TKI in hepatocellular carcinoma: a multicenter study.

Journal: BMC cancer

Published: January 10, 2023

Tumor Radiomic Features on Pretreatment MRI to Predict Response to Lenvatinib plus an Anti-PD-1 Antibody in Advanced Hepatocellular Carcinoma: A Multicenter Study.

Journal: Liver cancer

Published: June 16, 2022

Advances in postoperative adjuvant therapy for primary liver cancer.

Journal: World journal of gastrointestinal oncology

Published: December 29, 2021

Electron Microscopy-Based Comparison and Investigation of the Morphology of Exosomes Derived from Hepatocellular Carcinoma Cells Isolated at Different Centrifugal Speeds.

Journal: Microscopy and microanalysis : the official journal of Microscopy Society of America, Microbeam Analysis Society, Microscopical Society of Canada

Published: February 14, 2020

Comprehensive investigation of p53, p21, nm23, and VEGF expression in hepatitis B virus-related hepatocellular carcinoma overall survival after hepatectomy.

Journal: Journal of Cancer

Published: February 01, 2019

Progression-free survival of up to 8 months of an advanced intrahepatic cholangiocarcinoma patient treated with apatinib: a case report.

Journal: OncoTargets and therapy

Published: November 16, 2017

Human papillomavirus as a potential risk factor for gastric cancer: a meta-analysis of 1,917 cases.

Journal: OncoTargets and therapy

Published: November 30, 2016